E12: Jamie Rhode on Why 95% of LPs Can Only Achieve a 10% IRR when the Mean Return is 50% IRR
How I Invest with David Weisburd
00:00
Investing with Different LPs and the Life Sciences Opportunity
The chapter discusses the importance of investing with different LPs to avoid groupthink and how the speaker's family office has benefited from investing with other family offices. They also delve into the opportunity set in the life sciences sector, highlighting FDA approvals and the role of M&A. Overall, they emphasize the importance of diversification and building a more diversified base to decrease volatility.
Transcript
Play full episode
